MA
Moody Aldrich Partners LLC
13F filer · CIK 0000936941Reported Jul 15, 2026
Net seller this quarter
13F portfolio value$557MU.S. long equity reported on 13F
Positions17533 new · 48 closed
Net flow last quarter-$131MBuys minus sells
Top 10 positions weight16.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 15, 2026175 positions | |||||
| $10.6M | 1.90% | 0.09% | -20.5% | Q3 2022 | |
| $9.65M | 1.73% | 0.17% | -24.9% | Q4 2025 | |
| $9.56M | 1.72% | 0.24% | -20.7% | Q1 2016 | |
| $9.23M | 1.66% | 0.09% | -11.9% | Q4 2016 | |
| $8.9M | 1.60% | 0.14% | +91.9% | Q2 2018 | |
| $8.55M | 1.54% | 0.09% | -21.2% | Q1 2021 | |
| $8.37M | 1.50% | 0.09% | -20.2% | Q4 2017 | |
| $8.22M | 1.48% | 0.08% | -35.7% | Q1 2025 | |
| $8.09M | 1.45% | 0.44% | -11.8% | Q3 2023 | |
| $8.01M | 1.44% | 0.10% | -6.4% | Q4 2024 | |
| $7.31M | 1.31% | 0.09% | +10.6% | Q2 2023 | |
| $7.27M | 1.31% | 0.14% | -9.2% | Q1 2025 | |
| $7.24M | 1.30% | 0.07% | New | Q2 2026 | |
| $7.19M | 1.29% | 0.34% | New | Q2 2026 | |
| $6.92M | 1.24% | 0.05% | -54.8% | Q4 2025 | |
| $6.7M | 1.20% | 0.07% | New | Q2 2026 | |
| $6.69M | 1.20% | 0.15% | -21.5% | Q4 2024 | |
| $6.59M | 1.18% | 0.10% | -21.5% | Q2 2025 | |
| $6.57M | 1.18% | 0.18% | Not reported | Q1 2026 | |
| $6.5M | 1.17% | 0.08% | -35.8% | Q4 2024 | |
| $6.47M | 1.16% | 0.16% | +27.7% | Q1 2016 | |
| $6.4M | 1.15% | 0.09% | +30.2% | Q3 2016 | |
| $6.38M | 1.15% | 0.07% | -12.1% | Q2 2024 | |
| $6.35M | 1.14% | 0.10% | +27.5% | Q1 2026 | |
| $6.27M | 1.13% | 0.05% | -20.5% | Q2 2025 | |
| $6.13M | 1.10% | 0.10% | -20.5% | Q1 2016 | |
| $5.88M | 1.06% | Not reported | -21.5% | Q4 2017 | |
| $5.88M | 1.06% | 0.09% | -21.1% | Q4 2018 | |
| $5.85M | 1.05% | 0.05% | -79.6% | Q1 2016 | |
| $5.79M | 1.04% | 0.08% | -21.5% | Q2 2024 | |
| $5.74M | 1.03% | 0.07% | -1.2% | Q3 2021 | |
| $5.7M | 1.02% | 0.16% | -9.7% | Q1 2016 | |
| $5.69M | 1.02% | 0.08% | -4.4% | Q4 2024 | |
| $5.69M | 1.02% | 0.05% | +93.5% | Q1 2026 | |
| $5.62M | 1.01% | 0.07% | Not reported | Q3 2018 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $5.47M | 0.98% | 0.14% | -20.4% | Q3 2023 |
| $5.44M | 0.98% | 0.16% | -21.5% | Q3 2024 | |
| $5.34M | 0.96% | 0.16% | Not reported | Q2 2022 | |
| $5.32M | 0.96% | 0.07% | +23.8% | Q2 2024 | |
| $5.29M | 0.95% | 0.08% | Not reported | Q3 2024 | |
| $5.21M | 0.94% | 0.18% | -21.5% | Q1 2016 | |
| $5.21M | 0.94% | 0.11% | -21.5% | Q1 2026 | |
| $5.2M | 0.93% | 0.01% | Not reported | Q1 2020 | |
| $5.18M | 0.93% | 0.03% | -27.5% | Q1 2021 | |
| $5.11M | 0.92% | 0.06% | Not reported | Q4 2024 | |
| $5.01M | 0.90% | 0.01% | Not reported | Q1 2025 | |
| $4.98M | 0.89% | 0.09% | -21.5% | Q1 2019 | |
| $4.97M | 0.89% | 0.14% | -5.6% | Q4 2022 | |
| $4.84M | 0.87% | 0.15% | Not reported | Q3 2018 | |
| $4.72M | 0.85% | 0.33% | New | Q2 2026 | |
| Q1 2026Reported Apr 20, 2026190 positions | |||||
| $10.8M | 1.95% | 0.30% | -1.1% | Q1 2016 | |
| $9.51M | 1.71% | 0.11% | -1.1% | Q3 2022 | |
| $9.4M | 1.70% | 0.48% | -1.0% | Q3 2023 | |
| $9.26M | 1.67% | 0.11% | Not reported | Q1 2021 | |
| $9.05M | 1.63% | 0.10% | -1.0% | Q4 2016 | |
| $8.98M | 1.62% | 0.11% | -1.0% | Q4 2017 | |
| $7.85M | 1.42% | 0.13% | -1.1% | Q1 2016 | |
| $7.3M | 1.32% | 0.12% | +12.2% | Q4 2018 | |
| $7.03M | 1.27% | 0.14% | New | Q1 2026 | |
| $6.99M | 1.26% | 0.08% | -48.0% | Q2 2024 | |
| $6.89M | 1.24% | 0.15% | +98.8% | Q1 2025 | |
| $6.87M | 1.24% | 0.39% | +8.3% | Q4 2025 | |
| $6.85M | 1.24% | 0.23% | +18.6% | Q1 2016 | |
| $6.79M | 1.22% | 0.20% | -1.0% | Q3 2024 | |
| $6.77M | 1.22% | 0.13% | -0.9% | Q2 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $6.66M | 1.20% | 0.17% | +66.1% | Q3 2023 |
| $6.62M | 1.19% | 0.27% | +6.5% | Q4 2025 | |
| $6.44M | 1.16% | 0.44% | +59.8% | Q2 2025 | |
| $6.43M | 1.16% | 0.06% | -1.0% | Q2 2025 | |
| $6.23M | 1.12% | 0.19% | -1.0% | Q4 2024 | |
| $6.22M | 1.12% | 0.12% | +22.3% | Q4 2025 | |
| $6.09M | 1.10% | 0.09% | +160.9% | Q4 2025 | |
| $6.08M | 1.10% | 0.04% | -22.2% | Q1 2021 | |
| $6.08M | 1.10% | Not reported | +1.7% | Q2 2024 | |
| $5.89M | 1.06% | 0.18% | Not reported | Q1 2016 | |
| $5.81M | 1.05% | 0.11% | -1.0% | Q2 2024 | |
| $5.77M | 1.04% | 0.12% | +46.2% | Q1 2025 | |
| $5.74M | 1.04% | 0.07% | -15.6% | Q2 2019 | |
| $5.71M | 1.03% | 0.13% | -1.0% | Q4 2024 | |
| $5.69M | 1.03% | 0.17% | New | Q1 2026 | |
| $5.68M | 1.02% | 0.08% | -33.2% | Q2 2023 | |
| $5.68M | 1.02% | 0.15% | -31.8% | Q4 2022 | |
| $5.64M | 1.02% | 0.04% | -42.1% | Q1 2023 | |
| $5.52M | 1.00% | 0.07% | Not reported | Q2 2021 | |
| $5.5M | 0.99% | 0.07% | +33.0% | Q3 2024 | |
| $5.46M | 0.98% | 0.03% | -1.1% | Q3 2025 | |
| $5.42M | 0.98% | 0.13% | +18.6% | Q2 2024 | |
| $5.27M | 0.95% | 0.03% | +1.5% | Q2 2023 | |
| $5.26M | 0.95% | Not reported | -1.0% | Q4 2017 | |
| $5.25M | 0.95% | 0.15% | +51.2% | Q2 2022 | |
| $5.23M | 0.94% | 0.11% | -1.1% | Q2 2024 | |
| $5.19M | 0.94% | 0.07% | -18.1% | Q3 2025 | |
| $5.14M | 0.93% | 0.15% | Not reported | Q3 2018 | |
| $5.09M | 0.92% | 0.08% | +1.5% | Q4 2024 | |
| $5M | 0.90% | 0.11% | +135.4% | Q4 2024 | |
| $4.99M | 0.90% | 0.04% | -54.4% | Q1 2024 | |
| $4.95M | 0.89% | 0.07% | +9.1% | Q3 2018 | |
| $4.84M | 0.87% | 0.11% | -2.8% | Q2 2024 | |
| $4.78M | 0.86% | 0.01% | +4.6% | Q1 2021 | |
| $4.74M | 0.86% | 0.07% | Not reported | Q3 2021 | |
| Q4 2025Reported Jan 30, 2026185 positions | |||||
| $12.3M | 2.30% | 0.17% | Not reported | Q2 2024 | |
| CFCADECadence Financial Corp | $11.9M | 2.22% | Not reported | -4.6% | Q2 2024 |
| $10.6M | 1.99% | 0.30% | -4.5% | Q1 2016 | |
| $10M | 1.87% | 0.07% | +83.3% | Q1 2023 | |
| $9.25M | 1.73% | 0.11% | +21.7% | Q4 2017 | |
| $9.2M | 1.72% | 0.10% | +52.4% | Q4 2016 | |
| $7.88M | 1.47% | Not reported | -4.6% | Q2 2024 | |
| $7.56M | 1.41% | 0.48% | -4.6% | Q3 2023 | |
| $7.36M | 1.37% | 0.08% | -21.8% | Q2 2019 | |
| $7.22M | 1.35% | 0.13% | +10.3% | Q1 2016 | |
| $7.2M | 1.34% | 0.05% | Not reported | Q1 2021 | |
| $7.07M | 1.32% | 0.07% | +15.0% | Q2 2025 | |
| $7.04M | 1.31% | 0.13% | -43.6% | Q2 2023 | |
| $7.03M | 1.31% | 0.12% | -4.4% | Q3 2022 | |
| $6.74M | 1.26% | 0.10% | -4.4% | Q1 2024 | |
| $6.59M | 1.23% | 0.21% | +41.5% | Q3 2024 | |
| $6.5M | 1.21% | 0.07% | -2.9% | Q2 2025 | |
| $6.42M | 1.20% | Not reported | -4.7% | Q4 2024 | |
| $6.4M | 1.20% | 0.16% | -4.6% | Q2 2025 | |
| $6.25M | 1.17% | 0.05% | -20.5% | Q2 2025 | |
| $6.02M | 1.12% | 0.36% | New | Q4 2025 | |
| $5.99M | 1.12% | 0.10% | -4.5% | Q4 2018 | |
| $5.81M | 1.08% | 0.18% | Not reported | Q1 2016 | |
| $5.71M | 1.06% | 0.00% | +31.7% | Q1 2016 | |
| $5.67M | 1.06% | 0.22% | -7.8% | Q4 2022 | |
| $5.5M | 1.03% | 0.06% | Not reported | Q2 2025 | |
| $5.41M | 1.01% | 0.19% | +25.7% | Q4 2024 | |
| $5.31M | 0.99% | 0.09% | Not reported | Q4 2024 | |
| $5.29M | 0.99% | Not reported | +62.6% | Q2 2025 | |
| $5.28M | 0.99% | 0.15% | Not reported | Q3 2018 | |
| $5.24M | 0.98% | 0.05% | -4.4% | Q3 2025 | |
| $5.15M | 0.96% | 0.11% | +116.2% | Q2 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $5.14M | 0.96% | 0.12% | -4.4% | Q3 2023 |
| $5.04M | 0.94% | 0.13% | Not reported | Q1 2024 | |
| RREVGREV Group, Inc. | $5.04M | 0.94% | 0.17% | -4.6% | Q1 2025 |
| $5.01M | 0.94% | 0.11% | -4.7% | Q2 2024 | |
| $5M | 0.93% | 0.06% | -4.7% | Q3 2021 | |
| $4.98M | 0.93% | 0.10% | New | Q4 2025 | |
| $4.83M | 0.90% | 0.11% | -4.6% | Q2 2024 | |
| $4.79M | 0.89% | 0.07% | Not reported | Q3 2025 | |
| $4.78M | 0.89% | 0.11% | -20.9% | Q2 2024 | |
| $4.76M | 0.89% | 0.12% | -4.6% | Q1 2019 | |
| $4.67M | 0.87% | 0.15% | -21.7% | Q2 2024 | |
| $4.61M | 0.86% | 0.14% | Not reported | Q1 2021 | |
| $4.59M | 0.86% | 0.08% | Not reported | Q3 2024 | |
| $4.5M | 0.84% | 0.07% | +12.7% | Q3 2016 | |
| $4.47M | 0.83% | 0.13% | -4.6% | Q4 2024 | |
| $4.44M | 0.83% | 0.15% | -23.3% | Q2 2024 | |
| $4.41M | 0.82% | 0.14% | +4.7% | Q1 2021 | |
| $4.4M | 0.82% | 0.06% | -19.6% | Q3 2019 | |
| Q3 2025Reported Oct 21, 2025187 positions | |||||
| CFCADECadence Financial Corp | $10.9M | 2.07% | Not reported | +4.8% | Q2 2024 |
| $10.5M | 2.00% | 0.31% | +6.2% | Q1 2016 | |
| $9.5M | 1.80% | 0.23% | -16.1% | Q2 2023 | |
| $9.46M | 1.80% | 0.06% | +12.5% | Q2 2025 | |
| $8.44M | 1.60% | Not reported | -3.7% | Q2 2024 | |
| $8.26M | 1.57% | 0.49% | -16.9% | Q3 2023 | |
| $7.51M | 1.42% | 0.10% | +9.1% | Q1 2024 | |
| $7.41M | 1.41% | 0.12% | -5.6% | Q3 2022 | |
| MMRUSMerus N.V. | $7.2M | 1.37% | 0.10% | -16.9% | Q3 2024 |
| $7.17M | 1.36% | 0.13% | -8.4% | Q4 2024 | |
| $7.12M | 1.35% | 0.10% | -15.8% | Q1 2025 | |
| $6.99M | 1.33% | 0.09% | -16.9% | Q4 2017 | |
| $6.77M | 1.29% | 0.24% | +84.5% | Q4 2022 | |
| $6.53M | 1.24% | Not reported | -0.8% | Q4 2024 | |
| $6.46M | 1.23% | 0.19% | -16.8% | Q2 2025 | |
| $6.25M | 1.19% | 0.07% | +18.8% | Q2 2025 | |
| $6.25M | 1.19% | 0.10% | -16.2% | Q2 2019 | |
| CACWANClearwater Analytics Holdings, Inc. | $6.18M | 1.17% | Not reported | -16.6% | Q3 2024 |
| $6.14M | 1.16% | 0.11% | -16.5% | Q4 2018 | |
| $6.1M | 1.16% | 0.09% | -22.0% | Q3 2020 | |
| $6.07M | 1.15% | 0.06% | -32.2% | Q2 2025 | |
| $6M | 1.14% | 0.12% | -16.2% | Q1 2016 | |
| $5.94M | 1.13% | 0.09% | -34.5% | Q2 2016 | |
| $5.91M | 1.12% | 0.14% | -9.7% | Q2 2024 | |
| $5.83M | 1.11% | 0.09% | +90.7% | Q4 2024 | |
| $5.82M | 1.10% | 0.12% | -16.9% | Q1 2019 | |
| $5.78M | 1.10% | 0.09% | -16.9% | Q3 2018 | |
| $5.77M | 1.09% | 0.05% | New | Q3 2025 | |
| $5.73M | 1.09% | 0.05% | +92.6% | Q1 2021 | |
| $5.72M | 1.09% | 0.06% | -15.6% | Q4 2016 | |
| $5.67M | 1.08% | 0.06% | +152.1% | Q2 2025 | |
| $5.66M | 1.07% | 0.07% | -16.2% | Q3 2019 | |
| $5.5M | 1.04% | 0.13% | -16.3% | Q1 2021 | |
| $5.25M | 1.00% | 0.15% | +131.6% | Q3 2018 | |
| $5.17M | 0.98% | 0.11% | -17.0% | Q2 2024 | |
| $4.98M | 0.94% | 0.04% | -39.6% | Q2 2023 | |
| RREVGREV Group, Inc. | $4.92M | 0.93% | 0.18% | -33.2% | Q1 2025 |
| $4.91M | 0.93% | 0.14% | +89.6% | Q1 2021 | |
| $4.88M | 0.92% | Not reported | -16.9% | Q2 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $4.81M | 0.91% | 0.12% | -16.2% | Q3 2023 |
| $4.78M | 0.91% | Not reported | -45.2% | Q4 2024 | |
| $4.71M | 0.89% | 0.05% | +221.0% | Q2 2025 | |
| $4.7M | 0.89% | 0.02% | -42.2% | Q3 2023 | |
| $4.7M | 0.89% | 0.12% | +93.4% | Q2 2025 | |
| $4.68M | 0.89% | 0.00% | -16.9% | Q1 2016 | |
| $4.65M | 0.88% | 0.07% | New | Q3 2025 | |
| $4.63M | 0.88% | 0.19% | +9.6% | Q2 2024 | |
| $4.59M | 0.87% | 0.13% | Not reported | Q2 2018 | |
| $4.57M | 0.87% | 0.15% | -16.9% | Q3 2024 | |
| $4.53M | 0.86% | 0.07% | Not reported | Q3 2021 | |
Premium opens every quarter this fund has filed